493 related articles for article (PubMed ID: 31649669)
1. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
Front Immunol; 2019; 10():2353. PubMed ID: 31649669
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
Thurner B; Haendle I; Röder C; Dieckmann D; Keikavoussi P; Jonuleit H; Bender A; Maczek C; Schreiner D; von den Driesch P; Bröcker EB; Steinman RM; Enk A; Kämpgen E; Schuler G
J Exp Med; 1999 Dec; 190(11):1669-78. PubMed ID: 10587357
[TBL] [Abstract][Full Text] [Related]
3. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas.
Chłopik A; Selim MA; Peng Y; Wu CL; Tell-Marti G; Paral KM; Shalin SC; Kraft S; Hsu CK; Shea CR; Puig S; Fernandez-Figueras MT; Biernat W; Ryś J; Marszalek A; Hoang MP
Hum Pathol; 2018 Mar; 73():176-183. PubMed ID: 29307625
[TBL] [Abstract][Full Text] [Related]
8. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
[TBL] [Abstract][Full Text] [Related]
9. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.
Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A
Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472
[TBL] [Abstract][Full Text] [Related]
12. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
Appay V; Jandus C; Voelter V; Reynard S; Coupland SE; Rimoldi D; Lienard D; Guillaume P; Krieg AM; Cerottini JC; Romero P; Leyvraz S; Rufer N; Speiser DE
J Immunol; 2006 Aug; 177(3):1670-8. PubMed ID: 16849476
[TBL] [Abstract][Full Text] [Related]
13. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
[TBL] [Abstract][Full Text] [Related]
14. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
[TBL] [Abstract][Full Text] [Related]
16. A Novel
Zhang L; Du J; Song Q; Zhang C; Wu X
J Immunol Res; 2022; 2022():1178874. PubMed ID: 35155685
[TBL] [Abstract][Full Text] [Related]
17. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.
Li HS; Liu C; Xiao Y; Chu F; Liang X; Peng W; Hu J; Neelapu SS; Sun SC; Hwu P; Watowich SS
Sci Signal; 2016 Sep; 9(447):ra94. PubMed ID: 27678219
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
19. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
20. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
